Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERLIN: Tarlatamab Maintenance After Sequential Chemo‑Radiotherapy in Limited-Stage SCLC
2024-515201-26-00Phase 2Authorised
- Sponsor
- Fundación GECP
- Start
- Oct 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Fundación GECP. Primary endpoint: Progression-free survival (primary). Planned start Oct 2025; status: authorised.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-515201-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515201-26-00.